Evolus to Participate in Two Upcoming Investor Conferences

NEWPORT BEACH, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. EOLS, a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two upcoming investor conferences.

Audio webcasts of Evolus' fireside chats at the Wells Fargo Securities Healthcare Conference and H.C. Wainwright 21^st Annual Global Investment Conference will be available on the investor relations section of Evolus' website at investors.evolus.com. Replays of the webcasts will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investors Contacts:
Ashwin Agarwal, Evolus, Inc.
Vice President, Finance, Investor Relations & Treasury
Tel: +1-949-284-4559
Email: IR@Evolus.com

Media Contacts:
Crystal Muilenburg, Evolus, Inc.
Vice President, Corporate Communications & Public Relations
Tel: +1-949-284-4506
Email: media@evolus.com